Comparative Analysis of Incretin-Based Therapies
For patients prioritizing cardiovascular and renal protection, choose semaglutide or dulaglutide; for those prioritizing weight loss with lower cardiovascular risk, choose tirzepatide; retatrutide remains investigational with insufficient human outcome data. 1, 2
Cardiovascular Outcomes
Semaglutide: Strongest CV Evidence
Semaglutide demonstrates the most robust cardiovascular benefit among these agents. In SUSTAIN-6, semaglutide reduced MACE by 26% (HR 0.74,95% CI: 0.58-0.95), driven primarily by a 39% reduction in non-fatal stroke 3. The SELECT trial extended these findings to patients with obesity and established CVD without diabetes, showing a 20% reduction in 3-point MACE over 40 months, earning FDA approval for secondary cardiovascular risk reduction 2. This represents high certainty evidence for cardiovascular mortality and MACE reduction 1.
Dulaglutide: Proven CV Benefit
The REWIND trial demonstrated that dulaglutide reduced MACE-3 and other cardiovascular outcomes without increased hypoglycemia risk, regardless of baseline HbA1c 4. Dulaglutide has moderate to high certainty evidence for cardiovascular benefits 1.
Tirzepatide: Uncertain CV Evidence
Tirzepatide's cardiovascular benefit remains uncertain with only low to very low certainty evidence 1. The SURPASS-CVOT showed tirzepatide was non-inferior to dulaglutide for MACE but did not demonstrate superiority 5, 6. A post-hoc analysis suggested tirzepatide may reduce a 6-component cardiorenal composite (HR 0.84,95% CI: 0.79-0.90) 6, but this was exploratory. Real-world data showed tirzepatide had lower modified MACE versus dulaglutide (HR 0.80,95% CI: 0.65-0.99), driven by reduced all-cause mortality, but was similar to semaglutide 7. Meta-analyses show inconsistent signals—myocardial infarction reduction was observed (RR 0.63), but overall MACE reduction was not statistically significant (RR 0.79, p=0.245) 8.
Critical caveat: The 2025 BMJ guideline explicitly states that when choosing between GLP-1 RAs and tirzepatide, clinicians must weigh the higher certainty of cardiovascular and kidney benefits (offered by GLP-1 RAs) against larger weight loss benefits (offered by tirzepatide) 1.
Retatrutide: No Human CV Data
Retatrutide has only preclinical data in db/db mice showing potential benefits 9. There are no published cardiovascular outcome trials in humans—this agent remains investigational.
Renal Outcomes
Semaglutide: Proven Renal Protection
The FLOW trial demonstrated that semaglutide 1.0 mg weekly significantly reduced major kidney disease events in patients with T2DM and CKD 4. Semaglutide prevents new-onset macroalbuminuria, reduces urinary albumin excretion, and slows eGFR decline 4.
GLP-1 RAs Generally: Moderate-High Certainty
GLP-1 receptor agonists as a class have moderate to high certainty evidence for kidney benefits 1. The 2025 BMJ guideline gives GLP-1 RAs a strong recommendation for adults at higher cardiovascular and kidney risk 1.
Tirzepatide: Limited Renal Data
Tirzepatide showed slower decline in renal function compared to dulaglutide in SURPASS-CVOT 5, and the post-hoc analysis included kidney outcomes in the composite endpoint 6. However, the guideline explicitly notes "currently uncertain cardiovascular and kidney benefits" for tirzepatide 1. The evidence certainty is low to very low 1.
Retatrutide: Preclinical Only
Animal studies suggest retatrutide improves renal function markers and reduces inflammation/fibrosis in diabetic kidneys 9, but human renal outcome data are absent.
Weight Loss
Tirzepatide: Superior Weight Loss
Tirzepatide produces the largest weight reduction among approved agents. SURMOUNT-1 showed 22.5% weight loss at 72 weeks with the 15 mg dose, with nearly 40% of participants losing ≥25% body weight 2. SURMOUNT-3 and SURMOUNT-4 demonstrated up to 26.6% and 26% weight reduction respectively 2. In patients with T2DM (SURMOUNT-2), weight loss was 12.8-14.7% 2. The BMJ guideline notes moderate certainty evidence for mean 8.63 kg weight loss (relative to 90 kg baseline) 1.
Semaglutide: Excellent Weight Loss
STEP-1 showed 16.9% weight reduction at 68 weeks with semaglutide 2.4 mg, maintained at 16.7% in STEP-5's second year 2. Oral semaglutide 50 mg achieved 17.1% weight loss at 68 weeks (OASIS-1) 2. Semaglutide has the highest efficacy for weight loss among GLP-1 RAs 4.
Dulaglutide: Modest Weight Loss
GLP-1 RAs generally produce 5-10% weight loss in T2DM patients 4. Dulaglutide falls within this range but is less potent than semaglutide or tirzepatide.
Retatrutide: Promising Preclinical Data
Animal studies show retatrutide was "most effective in improving body weight" compared to liraglutide and tirzepatide in db/db mice 9. Phase 2 human trials suggest substantial weight loss, but comprehensive data are pending 10.
Clinical Decision Algorithm
For Patients with Established CVD or High CV Risk:
- First choice: Semaglutide (strongest CV evidence, FDA-approved for secondary prevention) 2, 3
- Alternative: Dulaglutide (proven MACE reduction) 4
- If prioritizing weight loss over CV certainty: Tirzepatide, but must add or continue SGLT-2 inhibitor 1
For Patients with CKD:
- Semaglutide (FLOW trial evidence) 4
- Combine with SGLT-2 inhibitor (highest certainty for kidney protection) 1
For Patients with Obesity, Lower CV/Renal Risk:
- Tirzepatide (superior weight loss, weak recommendation) 1
- Semaglutide (excellent weight loss with CV/renal certainty) 2
For Patients with Obesity AND High CV/Renal Risk:
This requires nuanced decision-making 1:
- If replacing GLP-1 RA with tirzepatide for weight loss, initiate or continue SGLT-2 inhibitor 1
- Tirzepatide should generally not replace medications effective in reducing CV/kidney complications 1
- Consider patient values: CV/kidney protection certainty vs. greater weight loss 1
Critical Pitfalls
Do not assume tirzepatide equals semaglutide for CV protection—the evidence certainty differs markedly 1, 8
Never combine tirzepatide with GLP-1 RAs—can combine with SGLT-2 inhibitors 1
Retatrutide is investigational—no human outcome data for CV or renal endpoints 9, 10
Gastrointestinal adverse events are more common with tirzepatide (42.5%) than dulaglutide (35.9%) 6
For established heart failure, SGLT-2 inhibitors may be preferred over any incretin-based therapy 1
Evidence Strength Summary
| Agent | CV Evidence | Renal Evidence | Weight Loss | Overall Certainty |
|---|---|---|---|---|
| Semaglutide | High | Moderate-High | High | Highest |
| Dulaglutide | Moderate-High | Moderate | Moderate | High |
| Tirzepatide | Low-Very Low | Low-Very Low | Moderate | Uncertain for CV/renal |
| Retatrutide | None (human) | None (human) | Promising | Investigational |
The 2025 BMJ living guideline emphasizes that recommendations for tirzepatide may require updating as more evidence accumulates regarding cardiovascular and kidney complications 1.